Physician profile
John S Goff
NPI 1942231832
$38,046.51
in general payments reported to CMS, 2019-2025
37 companies · $696 in 2025
The $696 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19K · 2020: $6,501 · 2021: $4,296 · 2022: $4,206 · 2023: $2,309 · 2024: $977 · 2025: $696.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,836 · Education: $84.00 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $62.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,835.55 |
| Education | $84.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $62.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $28,851.46 | 2019-2024 | |
| Abbvie INC. | $2,947.61 | 2019-2025 | |
| Gilead Sciences, INC. | $657.55 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $606.16 | 2019-2024 | Entyvio |
| E.R. Squibb & Sons, L.L.C. | $522.11 | 2021-2023 | Zeposia |
| Janssen Biotech, INC. | $511.38 | 2019-2025 | Stelara, Tremfya |
| Boston Scientific Corporation | $463.46 | 2019-2023 | |
| Phathom Pharmaceuticals, INC. | $275.63 | 2024-2025 | Voquezna |
| Celgene Corporation | $247.40 | 2022-2023 | Zeposia |
| Allergan, INC. | $232.51 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $232.44 | 2021-2023 | Xifaxan |
| Lilly USA, LLC | $225.12 | 2023-2024 | Omvoh |
| Aimmune Therapeutics, INC. | $208.75 | 2023 | |
| Janssen Scientific Affairs, LLC | $201.39 | 2019-2022 | |
| Intuitive Surgical, INC. | $200.08 | 2022 |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $194.05 | 2019-2024 | |
| Nestle Healthcare Nutrition INC. | $178.56 | 2022-2023 | |
| Genzyme Corporation | $175.32 | 2022-2024 | |
| Ardelyx, INC. | $145.87 | 2023-2025 | Ibsrela |
| Madrigal Pharmaceuticals | $131.63 | 2025 | Rezdiffra |
| Bayer Healthcare Pharmaceuticals INC. | $124.63 | 2019 | |
| Novo Nordisk INC | $109.27 | 2025 | |
| Biocompatibles, INC. | $92.89 | 2019 | |
| Braintree Laboratories, INC. | $81.74 | 2019-2020 | |
| Olympus America INC. | $71.09 | 2019-2022 | |
| Qol Medical, LLC | $43.96 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $41.89 | 2019 | |
| Digestive Care, INC. | $40.32 | 2021 | |
| Echosens North America, INC. | $37.57 | 2019-2024 | Fibroscan |
| Cook Medical LLC | $36.66 | 2022 | |
| Ethicon US, LLC | $35.48 | 2019-2023 | Linx Reflux Management System |
| Alnylam Pharmaceuticals INC. | $29.33 | 2022 | |
| Blueprint Medicines Corporation | $26.86 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $26.52 | 2023 | Dupixent |
| Ucb, INC. | $25.78 | 2019 | |
| Shionogi INC | $14.04 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Goff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.